Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
| ▸ | MARS1 | P56192 | 1/20 | 0.36 |
| ▸ | GOT1 | P17174 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4669243 | 0.87 | CASR (0.39) | KMT2AMEN1CASRMAPTLMNA | |
| SCHEMBL4669092 | 0.85 | KDR (0.41) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL4667381 | 0.82 | ALDH1A1 (0.44) | KMT2AMEN1MAPTPOLBALDH1A1 | |
| SCHEMBL4667387 | 0.81 | CA12 (0.39) | KMT2AMEN1CASRMAPTPOLB | |
| SCHEMBL4667399 | 0.81 | KDR (0.39) | KMT2AMEN1CASRMAPTLMNA | |
| SCHEMBL4670195 | 0.81 | ALDH1A1 (0.43) | KMT2AMEN1MAPTPOLBALDH1A1 | |
| SCHEMBL4668883 | 0.80 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4668960 | 0.77 | CXCR2 (0.38) | KMT2AMEN1MAPTPOLBHPGD | |
| SCHEMBL4667980 | 0.77 | MAPK1 (0.55) | KMT2AMEN1MAPTLMNAKDR | |
| SCHEMBL4667913 | 0.76 | MAPT (0.39) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1129689-B1 | Keratinous fiber dyeing composition comprising N-(2-hydroxybenzene)-carbamate or N-(2-hydroxybenzene)urea derivatives as coupling agents and process for dyeing | OREAL (FR) | 2008-07-09 | — | — | EP | claimed |
| US-6635091-B2 | Oxidation color dye and coupler | L'OREAL S. A. (FR) | 2003-10-21 | — | — | US | claimed |
| US-20020178512-A1 | Oxidation dyeing composition for keratinous fibres comprising a n-(2-hydrobenzene)-carbamate or a n-(2-hydroxy-benzene)-urea and a pyrazolopyrimine, dyeing methods | L'OREAL SA (FR) | 2002-12-05 | — | — | US | claimed |
| EP-1175198-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES COMPRISING A N-(2-HYDROBENZENE)-CARBAMATE OR A N-(2-HYDROXY-BENZENE)-UREA AND A PYRAZOLOPYRIMINE, DYEING METHODS | L'OREAL (FR) | 2002-01-30 | — | — | EP | claimed |
| US-20010034914-A1 | Compositions for the oxidation dyeing of keratinous fibers comprising at least one coupler, and dyeing methods | L'OREAL S.A. (FR) | 2001-11-01 | — | — | US | claimed |
| EP-1129689-A2 | Keratinous fiber dyeing composition comprising N-(2-hydroxybenzene)-carbamate or N-(2-hydroxybenzene)urea derivatives as coupling agents and process for dyeing | L'OREAL (FR) | 2001-09-05 | — | — | EP | claimed |
| WO-2001062220-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES COMPRISING A N-(2-HYDROBENZENE)-CARBAMATE OR A N-(2-HYDROXY-BENZENE)-UREA AND A PYRAZOLOPYRIMINE, DYEING METHODS | L'OREAL (FR) | 2001-08-30 | — | — | WO | claimed |
| EP-1129689-B1 | Keratinous fiber dyeing composition comprising N-(2-hydroxybenzene)-carbamate or N-(2-hydroxybenzene)urea derivatives as coupling agents and process for dyeing | OREAL (FR) | 2008-07-09 | — | — | EP | disclosed |
| US-6635091-B2 | Oxidation color dye and coupler | L'OREAL S. A. (FR) | 2003-10-21 | — | — | US | disclosed |
| US-20020178512-A1 | Oxidation dyeing composition for keratinous fibres comprising a n-(2-hydrobenzene)-carbamate or a n-(2-hydroxy-benzene)-urea and a pyrazolopyrimine, dyeing methods | L'OREAL SA (FR) | 2002-12-05 | — | — | US | disclosed |
| EP-1175198-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES COMPRISING A N-(2-HYDROBENZENE)-CARBAMATE OR A N-(2-HYDROXY-BENZENE)-UREA AND A PYRAZOLOPYRIMINE, DYEING METHODS | L'OREAL (FR) | 2002-01-30 | — | — | EP | disclosed |
| US-20010034914-A1 | Compositions for the oxidation dyeing of keratinous fibers comprising at least one coupler, and dyeing methods | L'OREAL S.A. (FR) | 2001-11-01 | — | — | US | disclosed |
| EP-1129689-A2 | Keratinous fiber dyeing composition comprising N-(2-hydroxybenzene)-carbamate or N-(2-hydroxybenzene)urea derivatives as coupling agents and process for dyeing | L'OREAL (FR) | 2001-09-05 | — | — | EP | disclosed |
| WO-2001062220-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES COMPRISING A N-(2-HYDROBENZENE)-CARBAMATE OR A N-(2-HYDROXY-BENZENE)-UREA AND A PYRAZOLOPYRIMINE, DYEING METHODS | L'OREAL (FR) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034914-A1 | Compositions for the oxidation dyeing of keratinous fibers comprising at least one coupler, and dyeing methods | KRT18, FH, FGB | KMT2A 1017/4885MEN1 2803/4885CASR 2782/4885 |
| US-20020178512-A1 | Oxidation dyeing composition for keratinous fibres comprising a n-(2-hydrobenzene)-carbamate or a n-(2-hydroxy-benzene)-urea and a pyrazolopyrimine, dyeing methods | FH, KRT18, CYB5R3 | KMT2A 2099/4885MEN1 4487/4885CASR 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.